Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study.
The epidemiology and pathophysiology of cancer-associated bone disease was reviewed in a new paper published by an International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Working Group.
A review of calcium and vitamin D supplementation trials revealed that current recommended doses are inadequate to prevent bone mineral density loss in women undergoing breast cancer therapy.
FDA-related news items of relevance from the month of June, 2013.
When patients with giant-cell tumor of the bone were treated with denosumab, which is a drug targeted against a protein that promotes bone destruction, the number of tumor giant cells decreased and new bone formation increased.
Calcium and/or vitamin D supplementation at commonly recommended doses does not prevent bone loss from androgen-deprivation therapy.
Denosumab better prevents skeletal complications, ups health-related QoL versus zoledronic acid.
A history of periodontitis may be associated with an increased risk of HPV-positive tumors in persons with head and neck squamous cell carcinoma.
Study finds loss evident in men treated with ADT for nonmetastatic, hormone-sensitive prostate cancer.
The risk of bone loss resulting from breast and prostate cancer treatment has been highlighted by researchers in Canada.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|